The ICF2 gene Zbtb24 specifically regulates the differentiation of B1 cells via promoting heme synthesis

Jun Wang, He Gao, Sai Zhao, Xiaoqiu Dai, Xiao-Yuan Qin, Wei‐Long Zheng, Can Zhu, Hong-Min Wang, Xuemei Zhu, Fang‐Yuan Gong, Xiaoming Gao, Ying ZhaobioRxiv 2023 · DOI

TL;DR

Researchers have identified the gene Zbtb24 as a critical, subset-specific regulator of B1 cell differentiation. By promoting heme synthesis and mTORC1 signaling, Zbtb24 enables these innate-like B cells to transform into antibody-secreting plasma cells, providing a new mechanistic explanation for the immunodeficiency seen in ICF2 syndrome patients.

What Problem Does This Paper Address?

Immunodeficiency, Centromeric Instability, and Facial Anomalies syndrome 2 (ICF2) is a rare, devastating genetic disorder. Patients suffer from recurrent infections due to low levels of serum antibodies, yet the underlying cellular "why" has remained elusive.

While we know that mutations in the ZBTB24 gene cause ICF2, previous research yielded conflicting clues. Some studies suggested it was involved in DNA repair, while others pointed toward memory B cell formation. This paper tackles a fundamental gap: How does Zbtb24 specifically control B cell function? The authors set out to determine if the gene acts as a "master switch" for specific B cell subsets and what metabolic pathways it manipulates to drive antibody production.

Methods

To isolate the role of Zbtb24 in the immune system, the authors employed a sophisticated toolkit:

  • Conditional Knockout Mice: Since global deletion of Zbtb24 is lethal in mice, they generated a B-cell-specific knockout ($Zbtb24^{B-CKO}$) using the Cre-Lox system. This allowed them to study the gene's function specifically within the B cell lineage without affecting the rest of the animal's development.
  • Adoptive Transfer: They purified B1 cells from knockout mice and "transplanted" them into $Rag2^{-/-}$ mice (which lack their own B and T cells) to observe how these specific cells behave in a complex living environment.
  • Metabolic Profiling: Using RNA-Seq and Gene Set Enrichment Analysis (GSEA), the team looked at which pathways were "broken" in the absence of Zbtb24. They specifically measured intracellular reactive oxygen species (ROS), mitochondrial mass, and protoporphyrin IX (PPIX)—a precursor to heme.
  • Rescue Experiments: In a classic "prove it" move, they added exogenous hemin (a form of heme) to knockout cell cultures to see if they could bypass the genetic defect and restore normal cell function.

Datasets

The study relied on several high-throughput datasets:

  • RNA-Seq Data: Comprehensive transcriptomic profiles of purified splenic and peritoneal B cells, both resting and activated. These are deposited in the GEO database under accessions GSE241746 and GSE241747.
  • Reference Databases: The team utilized the MSigDB (Molecular Signatures Database) for GSEA, focusing on Hallmark, KEGG, and GO gene sets to identify dysregulated metabolic and signaling pathways.

Key Insights and Ideas

  • The B1 vs. B2 Divide: The most striking finding is that Zbtb24 is almost entirely dispensable for "classical" B2 cells (the ones that make high-affinity antibodies in lymph nodes). Instead, it is a specialized requirement for B1 cells—innate-like cells that live in the gut and body cavities and provide the first line of defense against pathogens.
  • Heme as a Signaling Molecule: We usually think of heme in the context of red blood cells and oxygen. Here, the authors show that B1 cells require a massive "burst" of heme synthesis to differentiate. Heme acts as a signal to turn off Bach2, a protein that normally acts as a brake on plasma cell differentiation.
  • The mTORC1 Connection: The study links Zbtb24 to the mTORC1 pathway, a central sensor of cellular nutrients and energy. Without Zbtb24, B1 cells fail to ramp up mTORC1 activity, leading to a metabolic "stall" that prevents them from becoming antibody factories.
  • Uncoupling Division from Differentiation: Interestingly, Zbtb24-deficient B1 cells can still activate and divide normally; they just can't complete the final step of becoming plasma cells. This suggests that the gene regulates the quality of the cell's fate rather than its ability to survive or proliferate.

Key Results

  • Impaired TID-Ag Response: $Zbtb24^{B-CKO}$ mice showed significantly reduced antibody production when challenged with T-cell independent antigens (TID-Ags), which primarily trigger B1 cells.
  • 50-60% Reduction in Differentiation: In vitro, B1 cells lacking Zbtb24 showed a roughly 50-60% decrease in their ability to become $CD138^+$ plasma cells compared to wild-type cells.
  • Heme Rescue: Adding hemin to the culture media "almost completely abrogated" the differentiation defects, proving that the lack of heme was the primary bottleneck.
  • PPIX Deficit: Knockout B1 cells showed a pronounced reduction in PPIX levels (26.2% reduction in non-plasma cells), confirming a failure in the heme biosynthetic pathway.

Limitations and Future Work

While the study provides a clear mechanism in mice, the authors acknowledge a few hurdles:

  • Species Differences: Zbtb24 deficiency is embryonic lethal in mice but not in humans. This suggests that while the B cell pathways might be conserved, the gene likely has broader developmental roles in mice that differ from humans.
  • Direct vs. Indirect Regulation: It remains unclear if Zbtb24 binds directly to the promoters of heme synthesis genes or if it regulates them indirectly through other transcription factors.
  • Human B1 Cells: The markers for human B1 cells are still a subject of intense debate in immunology. Translating these findings to human clinical samples will require careful validation of which human B cell subsets correspond to the murine B1 population studied here.

This research highlights that the immune system doesn't use a "one size fits all" approach to metabolism, and understanding these subset-specific quirks could be the key to treating rare primary immunodeficiencies.

Summary updated

Abstract

ABSTRACT Loss-of-function mutations of ZBTB24 cause the Immunodeficiency, Centromeric Instability and Facial Anomalies syndrome 2 (ICF2). ICF2 is a rare autosomal recessive disorder with immunological defects in serum antibodies and circulating memory B cells, indicating an essential role of ZBTB24 in the terminal differentiation of B cells. Here we generated B-cell specific Zbtb24-deficient mice and systemically investigated its role in B cell development and function both in vivo and in vitro . Zbtb24 is dispensable for B cell development & maintenance in naive mice. Surprisingly, B-cell specific deletion of Zbtb24 does not evidently compromise germinal center reactions and the resulting primary & secondary antibody responses induced by T-cell dependent antigens, but significantly inhibits T-cell independent antigen-elicited antibody productions in vivo . At the cellular level, Zbtb24-deficiency specifically impedes the plasma cell differentiation of B1 cells without impairing their survival, activation and proliferation in vitro . Mechanistically, Zbtb24-ablation attenuates heme biosynthesis partially through mTORC1 in B1 cells, and addition of exogenous hemin abrogates the differentiation defects of Zbtb24-null B1 cells. Our study suggests that the defected B1 functions may contribute to recurrent infections in ICF2 patients, and discloses a B1-specific role of Zbtb24 in regulating plasma cell differentiation and antibody production, which is relevant for barrier defenses against invading pathogens.
BibTeX
@misc{wang2023icf,
  author = {Jun Wang and He Gao and Sai Zhao and Xiaoqiu Dai and Xiao-Yuan Qin and Wei‐Long Zheng and Can Zhu and Hong-Min Wang and Xuemei Zhu and Fang‐Yuan Gong and Xiaoming Gao and Ying Zhao},
  title = {{The ICF2 gene Zbtb24 specifically regulates the differentiation of B1 cells <i>via</i> promoting heme synthesis}},
  year = {2023},
  doi = {10.1101/2023.12.23.573176},
  howpublished = {bioRxiv},
}
Figure